FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555506446> ?p ?o ?g. }

• W2555506446 endingPage "e667" @default.
• W2555506446 startingPage "e665" @default.
• W2555506446 abstract "Although intra-ocular antivascular endothelial growth factor (VEGF) injections are the standard of care for patients with diabetic macular oedema (DME), some fail this treatment. This begets the need for alternative therapies for these patients. Multiple basic science studies have demonstrated low concentrations of danazol significantly enhance endothelial barrier function and lower vascular permeability, making it a prime candidate therapy for DME (Thomas et al. 2012; Thomas et al. 2007). The results of a subsequent Phase 2 randomized controlled trial (RCT) indicated danazol was safe and its efficacy was dependent on body mass index (BMI) (Yau et al. 2012). We are now reporting an interesting observation from a second Phase 2 RCT, where we have identified a synergistic interaction between danazol and renin–angiotensin system (RAS) inhibitors. These data come from a multicenter, double-blind, RCT evaluating the efficacy and safety of two low doses of oral danazol (0.5 mg/BMI/day or 1 mg/BMI/day) in adults with DME, compared to placebo. Twenty-one ophthalmology clinics across the United States were included in the trial. The conduct of this trial was in accordance with the Declaration of Helsinki. The primary and secondary outcomes were change from baseline to the end of the double-blind phase in best-corrected visual acuity (BCVA) and central retinal thickness (CRT, measured by optical coherence tomography, μm). Three observations (one in each group) were excluded due to being more than three standard deviations away from the group mean. Overall, there were 425 eyes included in the trial, equally distributed amongst the three treatment groups. The groups were similar at baseline, with 53% having failed a previous anti-VEGF therapy. We confirmed the interaction of danazol with BMI. The second BMI quartile (27.7–31.3 BMI) had the most significant response to danazol; all results are presented for this quartile (n = 107). More interestingly, we also discovered a second, synergistic interaction with RAS inhibitors (Fig. 1). Seventy per cent of eyes in the second BMI quartile were on a concomitant RAS inhibitor. The 0.5 mg danazol group showed a significant 5.8-letter increase in BCVA from baseline at 12 weeks (p < 0.001); this was significantly larger (p = 0.01) than the 0.8-letter, non-significant increase from baseline observed in the placebo group. Concomitant RAS inhibitor use was not shown to modify the effect of 1 mg danazol/BMI on BCVA. In the remaining 30% of eyes not on a concomitant RAS inhibitor, all treatment groups did not show a significant increase from baseline in BCVA. It was only when the 0.5 mg danazol/BMI treatment was combined with RAS inhibitors that significant improvements from baseline were seen in both BCVA and CRT at every visit (Fig. 1). In subjects on a concomitant RAS inhibitor, both the 0.5 mg and 1 mg danazol/BMI treatment groups showed significant decreases from baseline in CRT (−49.0 μm, p = 0.01; −39.3 μm, p = 0.03), and the decrease in the 0.5 mg danazol/BMI group was significantly greater than the +10.2 μm increase seen in the placebo group (p = 0.03). It is important to note the RAS inhibitor interaction was examined across all BMI quartiles. Only the second BMI quartile showed a significant interaction, again suggesting the 0.5 mg/BMI/day dosage was optimal in this BMI range. The combination of oral RAS inhibitors and oral low-dose danazol might be a painless, safe and efficacious therapy for a subset of patients suffering from DME. Combination therapies addressing multiple disease pathways are likely to be more resilient to physiological compensatory mechanisms than therapies addressing single pathways. With an estimated one to two million people in the United States suffering from DME and on a path towards permanent blindness, alternate therapies to intra-ocular injections must be explored, particularly for patients refractory to available therapies.(Das et al. 2015; Bar-Or et al. 2012)." @default.
• W2555506446 created "2016-11-30" @default.
• W2555506446 creator A5027046934 @default.
• W2555506446 creator A5031497734 @default.
• W2555506446 creator A5050297384 @default.
• W2555506446 date "2016-11-19" @default.
• W2555506446 modified "2023-10-18" @default.
• W2555506446 title "Potential beneficial effect of low-dose danazol in combination with renin-angiotensin system inhibitors in diabetic macular oedema" @default.
• W2555506446 cites W2005409914 @default.
• W2555506446 cites W2101694121 @default.
• W2555506446 cites W2111148089 @default.
• W2555506446 cites W2138480916 @default.
• W2555506446 doi "https://doi.org/10.1111/aos.13318" @default.
• W2555506446 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27864867" @default.
• W2555506446 hasPublicationYear "2016" @default.
• W2555506446 type Work @default.
• W2555506446 sameAs 2555506446 @default.
• W2555506446 citedByCount "2" @default.
• W2555506446 countsByYear W25555064462019 @default.
• W2555506446 countsByYear W25555064462020 @default.
• W2555506446 crossrefType "journal-article" @default.
• W2555506446 hasAuthorship W2555506446A5027046934 @default.
• W2555506446 hasAuthorship W2555506446A5031497734 @default.
• W2555506446 hasAuthorship W2555506446A5050297384 @default.
• W2555506446 hasBestOaLocation W25555064461 @default.
• W2555506446 hasConcept C126322002 @default.
• W2555506446 hasConcept C126894567 @default.
• W2555506446 hasConcept C134018914 @default.
• W2555506446 hasConcept C198710026 @default.
• W2555506446 hasConcept C2777416354 @default.
• W2555506446 hasConcept C2779522080 @default.
• W2555506446 hasConcept C71924100 @default.
• W2555506446 hasConcept C84393581 @default.
• W2555506446 hasConcept C98274493 @default.
• W2555506446 hasConceptScore W2555506446C126322002 @default.
• W2555506446 hasConceptScore W2555506446C126894567 @default.
• W2555506446 hasConceptScore W2555506446C134018914 @default.
• W2555506446 hasConceptScore W2555506446C198710026 @default.
• W2555506446 hasConceptScore W2555506446C2777416354 @default.
• W2555506446 hasConceptScore W2555506446C2779522080 @default.
• W2555506446 hasConceptScore W2555506446C71924100 @default.
• W2555506446 hasConceptScore W2555506446C84393581 @default.
• W2555506446 hasConceptScore W2555506446C98274493 @default.
• W2555506446 hasIssue "7" @default.
• W2555506446 hasLocation W25555064461 @default.
• W2555506446 hasLocation W25555064462 @default.
• W2555506446 hasOpenAccess W2555506446 @default.
• W2555506446 hasPrimaryLocation W25555064461 @default.
• W2555506446 hasVolume "95" @default.
• W2555506446 isParatext "false" @default.
• W2555506446 isRetracted "false" @default.
• W2555506446 magId "2555506446" @default.
• W2555506446 workType "article" @default.